Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (51-60 of 203) with videos related to

Pageof 21
Sort By:
Blood|January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoTakashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 2020
Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful BenefitsDaniel R Richardson, Norah L Crossnohere, Jaein Seo, et al.
Cancer Research|July 5, 2005
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivoRebecca C Osthus, Baktiar Karim, Julia E Prescott, et al.
Leukemia Research|July 12, 2014
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML)Joshua F Zeidner, Douglas E Gladstone, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade, B Douglas Smith, Steven D Gore, et al.
Current Medical Research and Opinion|June 13, 2019
Side effects from acute myeloid leukemia treatment: results from a national surveyNorah L Crossnohere, Daniel R Richardson, Crystal Reinhart, et al.
The Journal of Community and Supportive Oncology|March 27, 2015
Practice gaps and barriers to optimal care of hematologic malignancies in the United StatesSuzanne Murray, Kevin L Obholz, Andrew D Bowser, et al.
Expert Review of Hematology|November 17, 2015
Economic burden associated with acute myeloid leukemia treatmentAmer M Zeidan, Dalia Mahmoud, Izabela T Kucmin-Bemelmans, et al.
Leukemia & Lymphoma|May 10, 2017
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Syed Rizvi, et al.
Blood Neoplasia|October 2, 2025
Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world studyCurtis A Lachowiez, B Douglas Smith, Alexander Joseph Ambinder, et al.
Pageof 21

Showing results (51-60 of 203) with videos related to

Sort By:
Pageof 21
Blood|January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoTakashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 2020
Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful BenefitsDaniel R Richardson, Norah L Crossnohere, Jaein Seo, et al.
Cancer Research|July 5, 2005
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivoRebecca C Osthus, Baktiar Karim, Julia E Prescott, et al.
Leukemia Research|July 12, 2014
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML)Joshua F Zeidner, Douglas E Gladstone, Marianna Zahurak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade, B Douglas Smith, Steven D Gore, et al.
Current Medical Research and Opinion|June 13, 2019
Side effects from acute myeloid leukemia treatment: results from a national surveyNorah L Crossnohere, Daniel R Richardson, Crystal Reinhart, et al.
The Journal of Community and Supportive Oncology|March 27, 2015
Practice gaps and barriers to optimal care of hematologic malignancies in the United StatesSuzanne Murray, Kevin L Obholz, Andrew D Bowser, et al.
Expert Review of Hematology|November 17, 2015
Economic burden associated with acute myeloid leukemia treatmentAmer M Zeidan, Dalia Mahmoud, Izabela T Kucmin-Bemelmans, et al.
Leukemia & Lymphoma|May 10, 2017
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Syed Rizvi, et al.
Blood Neoplasia|October 2, 2025
Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world studyCurtis A Lachowiez, B Douglas Smith, Alexander Joseph Ambinder, et al.
Pageof 21